Improving the Safety of Oral Immunotherapy for Cow's Milk Allergy (SOCMA)

Imperial College London

Status: Completed

Conditions: Food Allergy

Treatments: Other: SLIT to cow's milk; Other: Low dose OIT; Other: Conventional OIT to cow's milk

Study type: Interventional

Funder types: Other

Identifiers

NCT02216175

18/LO/1070 (Other Identifier)

18SM4569

Details and patient eligibility

About

Allergy to cow's milk is the most common food allergy affecting children. There is currently no accepted routine clinical therapy to cure milk allergy. Recently studies have attempted to induce desensitisation using small daily doses of cow's milk, predominantly by the oral route (oral immunotherapy, OIT). Although this therapy works for some people, its effects are not generally long lasting and it is associated with significant side effects during protocol, including potentially life-threatening allergic reactions.

Pilot data suggests that sublingual immunotherapy (SLIT, where allergen is held under the tongue, rather than swallowed) can also induce a degree of desensitisation, but with fewer adverse events. However, the degree of desensitisation induced appears to be lower than that with oral immunotherapy.

The investigators wish to determine whether a sublingual pretreatment phase can improve the safety of conventional OIT in cow's milk allergy.

Enrollment: 68 patients

Sex: All

Ages: 6 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Allergic to 1.44g CM protein (approx. 40ml fresh milk) or less, at DBPCFC prior to randomisation
2. Informed consent of parent/legal guardian, patient assent where possible

Exclusion criteria

1. Required previous admission to an intensive care unit for management of an allergic reaction.
2. Significant symptoms of non---IgE---mediated CM allergy within the previous 12 months.
3. Children with a past history of CM allergy currently consuming CM-containing products other than extensively--heated milk in baked foods (e.g. biscuits, cakes).
4. Poorly controlled asthma within the previous 3 months (as defined by clinician judgement with reference to the ICON consensus), or asthma requiring treatment with >5 days oral corticosteroids within the previous 3 months.
5. Moderate---severe eczema, defined as requiring more than once daily application of 1% hydrocortisone as maintenance treatment despite appropriate use of emollients (eczema is not otherwise an exclusion criteria)
6. Clinically significant chronic illness (other than asthma, rhinitis or eczema)
7. History of symptoms of eosinophilic oesophagitis, irrespective of cause
8. Undergoing specific immunotherapy to another allergen and within the first year of treatment.
9. Receiving anti--IgE therapy, oral immunosuppressants, beta---blocker or ACE inhibitor.
10. Pregnancy
11. Unwilling or unable to fulfil study requirements

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

68 participants in 3 patient groups, including a placebo group

SLIT followed by Conventional OIT

Experimental group

Description:

Participants will receive up to 7 months of SLIT followed by 6 months conventional OIT to cow's milk

Treatment:

Other: Conventional OIT to cow's milk

Other: SLIT to cow's milk

Conventional OIT

Active Comparator group

Description:

Participants will receive up to 7 months of low dose OIT, followed by 6 months conventional OIT to cow's milk

Treatment:

Other: Low dose OIT

Other: Conventional OIT to cow's milk

Delayed start OIT

Placebo Comparator group

Description:

Participants will receive up to 7 months placebo, followed by 6 months conventional OIT to cow's milk

Treatment:

Other: Conventional OIT to cow's milk